In the USA, a new drug was approved for the treatment of patients with late stages of breast cancer
[ad_1]
The US Food and Drug Administration (FDA) has approved Gilead’s drug Trodelvy for the treatment of breast cancer. This is reported by Reuters. The drug will provide another treatment option for patients with the most common type of breast cancer, known as HR-positive/HER2-negative, and bladder and urinary tract cancer. Trodelvy will be prescribed to patients who have stopped responding to hormonal therapy and at least two previous courses of “chemo”. Photo: Gilead Gilead Chief Medical Officer Merdad Parsi says Trodelvy is a “really important option” for late-stage breast cancer that has no other effective treatment. Gilead’s Trodelvy is likely to compete with AstraZeneca’s Enhertu, which is also used to treat breast cancer. Therefore, medical experts predict that the level of consumption of Trodelvy will be “fairly modest”. It is expected that the drug can be prescribed to 6-8 thousand patients in the USA. It will be recalled that earlier the US Food and Drug Administration (FDA) approved Eli Lilly’s drug for a rare form of blood cancer. Also read: Indian eye drops linked to infections, blindness and one death in US
[ad_2]
Original Source Link
